Tocqueville Asset Management L.P. Sells 1,215 Shares of Edwards Lifesciences Co. (NYSE:EW)

Tocqueville Asset Management L.P. lowered its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.5% in the 4th quarter, Holdings Channel.com reports. The firm owned 82,570 shares of the medical research company’s stock after selling 1,215 shares during the quarter. Tocqueville Asset Management L.P.’s holdings in Edwards Lifesciences were worth $6,113,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Wealth Architects LLC bought a new position in Edwards Lifesciences in the 4th quarter worth $213,000. Terra Alpha Investments LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth about $1,598,000. Cibc World Markets Corp raised its stake in shares of Edwards Lifesciences by 14.5% in the fourth quarter. Cibc World Markets Corp now owns 93,645 shares of the medical research company’s stock worth $6,933,000 after buying an additional 11,873 shares during the period. Valued Retirements Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $214,000. Finally, GLOBALT Investments LLC GA bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at approximately $224,000. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. The Goldman Sachs Group raised their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Piper Sandler raised their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Citigroup upped their target price on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Barclays upped their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Hold” and an average target price of $79.95.

Insider Activity

In related news, Director Steven R. Loranger sold 5,739 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares of the company’s stock, valued at $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,189,770.56. This trade represents a 16.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $70.31 on Wednesday. The company has a market cap of $41.33 billion, a P/E ratio of 10.09, a P/E/G ratio of 4.82 and a beta of 1.12. The business’s 50 day moving average price is $71.61 and its 200-day moving average price is $70.35. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.